Search Results - Oncology

1 Results

Sort By:

SR-18465 for Inhibition of MMP-13 in Multiple Myeloma

This patent-pending technology is a SR-18465 compound, which is an osteoclastogenesis matrix metalloproteinase 13 (MMP-13) highly specific inhibitor for the treatment of multiple myeloma. The compound specifically inhibits MMP-13 rather than the entire MMP family of endogenous proteins. SR-18465 directly impacts the viability of several multiple myeloma...

Published: 8/2/2019 | Inventor(s): Gregg Fields, Conor Lynch

Keywords(s):

Category(s): Oncology